CA2651328A1 - T-cell vaccine - Google Patents
T-cell vaccine Download PDFInfo
- Publication number
- CA2651328A1 CA2651328A1 CA002651328A CA2651328A CA2651328A1 CA 2651328 A1 CA2651328 A1 CA 2651328A1 CA 002651328 A CA002651328 A CA 002651328A CA 2651328 A CA2651328 A CA 2651328A CA 2651328 A1 CA2651328 A1 CA 2651328A1
- Authority
- CA
- Canada
- Prior art keywords
- cells
- plp
- mog
- mbp
- peptides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title claims abstract description 182
- 229940030156 cell vaccine Drugs 0.000 title claims abstract description 30
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 278
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 191
- 238000000034 method Methods 0.000 claims abstract description 58
- 229960005486 vaccine Drugs 0.000 claims abstract description 54
- 229920001184 polypeptide Polymers 0.000 claims abstract description 42
- 230000000890 antigenic effect Effects 0.000 claims abstract description 22
- 230000004936 stimulating effect Effects 0.000 claims abstract description 15
- 210000004027 cell Anatomy 0.000 claims description 48
- 239000000427 antigen Substances 0.000 claims description 39
- 108091007433 antigens Proteins 0.000 claims description 39
- 102000036639 antigens Human genes 0.000 claims description 39
- 230000000638 stimulation Effects 0.000 claims description 34
- 150000001413 amino acids Chemical class 0.000 claims description 30
- 201000010099 disease Diseases 0.000 claims description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 18
- 108010058432 Chaperonin 60 Proteins 0.000 claims description 5
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims description 3
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims description 3
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims description 3
- 230000001404 mediated effect Effects 0.000 claims description 3
- 238000001514 detection method Methods 0.000 claims description 2
- 238000012544 monitoring process Methods 0.000 claims description 2
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 claims 3
- 102000006303 Chaperonin 60 Human genes 0.000 claims 1
- 108010000123 Myelin-Oligodendrocyte Glycoprotein Proteins 0.000 description 144
- 102000002233 Myelin-Oligodendrocyte Glycoprotein Human genes 0.000 description 144
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 134
- 102000047918 Myelin Basic Human genes 0.000 description 131
- 101710107068 Myelin basic protein Proteins 0.000 description 131
- 230000009257 reactivity Effects 0.000 description 51
- 238000003556 assay Methods 0.000 description 48
- 201000006417 multiple sclerosis Diseases 0.000 description 36
- 102000006386 Myelin Proteins Human genes 0.000 description 29
- 108010083674 Myelin Proteins Proteins 0.000 description 29
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 27
- 210000005012 myelin Anatomy 0.000 description 24
- 239000000203 mixture Substances 0.000 description 21
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 20
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 20
- 238000004458 analytical method Methods 0.000 description 19
- 210000000612 antigen-presenting cell Anatomy 0.000 description 18
- 108090000623 proteins and genes Proteins 0.000 description 18
- 102000004169 proteins and genes Human genes 0.000 description 17
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 15
- 108091008874 T cell receptors Proteins 0.000 description 14
- 238000004519 manufacturing process Methods 0.000 description 13
- 206010071068 Clinically isolated syndrome Diseases 0.000 description 11
- 108700028369 Alleles Proteins 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 230000012010 growth Effects 0.000 description 10
- 230000004044 response Effects 0.000 description 10
- 102000055324 Myelin Proteolipid Human genes 0.000 description 9
- 229920006226 ethylene-acrylic acid Polymers 0.000 description 9
- 102000000588 Interleukin-2 Human genes 0.000 description 8
- 108010002350 Interleukin-2 Proteins 0.000 description 8
- 108700021862 Myelin Proteolipid Proteins 0.000 description 8
- 230000002238 attenuated effect Effects 0.000 description 8
- 238000002255 vaccination Methods 0.000 description 8
- 230000005867 T cell response Effects 0.000 description 7
- 238000009171 T-cell vaccination Methods 0.000 description 7
- 230000028993 immune response Effects 0.000 description 6
- 230000004913 activation Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 102100038222 60 kDa heat shock protein, mitochondrial Human genes 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 108010047620 Phytohemagglutinins Proteins 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000001885 phytohemagglutinin Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 3
- 238000012935 Averaging Methods 0.000 description 3
- 102000003812 Interleukin-15 Human genes 0.000 description 3
- 108090000172 Interleukin-15 Proteins 0.000 description 3
- 101500027988 Mus musculus ADGRV1 subunit beta Proteins 0.000 description 3
- -1 PLP Proteins 0.000 description 3
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 230000003827 upregulation Effects 0.000 description 3
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 2
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 2
- 101100084046 Caenorhabditis elegans cyn-4 gene Proteins 0.000 description 2
- 101100131052 Caenorhabditis elegans mog-1 gene Proteins 0.000 description 2
- 101100476202 Caenorhabditis elegans mog-2 gene Proteins 0.000 description 2
- 101100331527 Caenorhabditis elegans mog-4 gene Proteins 0.000 description 2
- 101100184657 Caenorhabditis elegans mog-5 gene Proteins 0.000 description 2
- 102000006354 HLA-DR Antigens Human genes 0.000 description 2
- 108010058597 HLA-DR Antigens Proteins 0.000 description 2
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 2
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 2
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 2
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 2
- 101100137555 Mus musculus Prg2 gene Proteins 0.000 description 2
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 2
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000007503 antigenic stimulation Effects 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000003226 mitogen Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000000754 repressing effect Effects 0.000 description 2
- 238000011268 retreatment Methods 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- VZQHRKZCAZCACO-PYJNHQTQSA-N (2s)-2-[[(2s)-2-[2-[[(2s)-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]propanoyl]amino]prop-2-enoylamino]-3-methylbutanoyl]amino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)C(=C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCNC(N)=N VZQHRKZCAZCACO-PYJNHQTQSA-N 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 101100352418 Caenorhabditis elegans plp-1 gene Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 102000011786 HLA-A Antigens Human genes 0.000 description 1
- 108010075704 HLA-A Antigens Proteins 0.000 description 1
- 101000982010 Homo sapiens Myelin proteolipid protein Proteins 0.000 description 1
- 101001129124 Mannheimia haemolytica Outer membrane lipoprotein 1 Proteins 0.000 description 1
- 101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 description 1
- 101710094913 Myelin proteolipid protein Proteins 0.000 description 1
- 102100026784 Myelin proteolipid protein Human genes 0.000 description 1
- 101000761187 Odontomachus monticola U-poneritoxin(01)-Om1a Proteins 0.000 description 1
- 101000761124 Odontomachus monticola U-poneritoxin(01)-Om7a Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 210000004970 cd4 cell Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 229920006244 ethylene-ethyl acrylate Polymers 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000008004 immune attack Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000003093 intracellular space Anatomy 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 229940038309 personalized vaccine Drugs 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000012106 screening analysis Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 231100000617 superantigen Toxicity 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/22—Immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/414—Nervous system antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Rheumatology (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74661106P | 2006-05-05 | 2006-05-05 | |
| US60/746,611 | 2006-05-05 | ||
| US74790306P | 2006-05-22 | 2006-05-22 | |
| US60/747,903 | 2006-05-22 | ||
| PCT/US2007/068304 WO2007131210A2 (en) | 2006-05-05 | 2007-05-04 | T-cell vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2651328A1 true CA2651328A1 (en) | 2007-11-15 |
Family
ID=38668612
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002651328A Abandoned CA2651328A1 (en) | 2006-05-05 | 2007-05-04 | T-cell vaccine |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20100003228A1 (enExample) |
| EP (3) | EP2016414B1 (enExample) |
| JP (3) | JP2009536036A (enExample) |
| AU (1) | AU2007247869B2 (enExample) |
| CA (1) | CA2651328A1 (enExample) |
| DK (2) | DK2016414T3 (enExample) |
| ES (2) | ES2552667T3 (enExample) |
| IL (1) | IL195115A (enExample) |
| NZ (1) | NZ572644A (enExample) |
| PL (2) | PL2016414T3 (enExample) |
| PT (2) | PT2016414E (enExample) |
| WO (1) | WO2007131210A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL398077A1 (pl) * | 2012-02-10 | 2012-08-27 | Krzysztof Selmaj | Kompozycja farmaceutyczna oraz zastosowanie kompozycji do wytwarzania leku, do podawania naskórnego, do leczenia stwardnienia rozsianego |
| GB201300684D0 (en) * | 2013-01-15 | 2013-02-27 | Apitope Int Nv | Peptide |
| CN105992950A (zh) * | 2013-12-19 | 2016-10-05 | 欧普萨治疗股份有限公司 | T 细胞表位表达谱分析、制备 t 细胞组合物以及治疗疾病的方法 |
| KR101503341B1 (ko) * | 2014-03-12 | 2015-03-18 | 국립암센터 | 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법 |
| WO2016037123A2 (en) | 2014-09-05 | 2016-03-10 | Opexa Therapeutics, Inc. | Compositions and methods for treating b cell mediated autoimmune disorders |
| US10231033B1 (en) | 2014-09-30 | 2019-03-12 | Apple Inc. | Synchronizing out-of-band content with a media stream |
| AU2018206015B2 (en) | 2017-01-06 | 2019-05-30 | Eutilex Co., Ltd. | Anti-human 4-1 BB antibodies and use thereof |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5852225A (ja) * | 1981-09-22 | 1983-03-28 | Mitsui Pharmaceut Inc | 脱髄疾患治療剤 |
| US5766920A (en) * | 1982-08-11 | 1998-06-16 | Cellcor, Inc. | Ex vivo activation of immune cells |
| US4550086A (en) * | 1983-02-16 | 1985-10-29 | Dana-Farber Cancer Institute, Inc. | Monoclonal antibodies that recognize human T cells |
| IL69686A (en) * | 1983-09-11 | 1988-03-31 | Yeda Res & Dev | Compositions containing cell membrane proteins and process for their preparation |
| US4608365A (en) * | 1984-03-30 | 1986-08-26 | University Of Southern California | Treatment of neurologic functions |
| US4677061A (en) * | 1984-10-19 | 1987-06-30 | Genetic Systems Corporation | T-cell lymphocyte subset monitoring of immunologic disease |
| US4902680A (en) * | 1984-10-29 | 1990-02-20 | Chaovanee Aroonsakul | Treating central nervous system diseases |
| US4898857A (en) * | 1984-10-29 | 1990-02-06 | Chaovanee Aroonsakul | Treating control nervous system diseases |
| US4898856A (en) * | 1984-10-29 | 1990-02-06 | Chaovanee Aroonsakul | Method for treating central nervous system diseases |
| US4897389A (en) * | 1984-10-29 | 1990-01-30 | Chaovanee Aroonsakul | Treating central nervous system diseases |
| CA1296622C (en) * | 1986-08-12 | 1992-03-03 | Jeffrey E. Anderson | Method and apparatus for automated assessment of the immunoregulatory status of the mononuclear leukocyte immune system |
| US5849298A (en) * | 1987-06-24 | 1998-12-15 | Autoimmune Inc. | Treatment of multiple sclerosis by oral administration of bovine myelin |
| US5039660A (en) * | 1988-03-02 | 1991-08-13 | Endocon, Inc. | Partially fused peptide pellet |
| US5242687A (en) * | 1989-03-15 | 1993-09-07 | Tkb Associates Limited Partnership | Method of reducing cellular immune response involving T-cells using CD8-bearing antigen presenting cells |
| US5861164A (en) * | 1989-03-21 | 1999-01-19 | The Immune Response Corporation | Vaccination against diseases resulting from pathogenic responses by specific T cell populations |
| US6007815A (en) * | 1989-03-21 | 1999-12-28 | The Immune Response Corporation | Anti-idiotype vaccination against diseases resulting from pathogenic responses by specific T cell populations |
| US6221352B1 (en) * | 1989-03-21 | 2001-04-24 | The Immune Response Corporation | Method of preventing the proliferation of Vβ14 or Vβ17-Expressing T cells |
| US6207645B1 (en) * | 1989-03-21 | 2001-03-27 | The Immune Response Corporation | Vaccination and methods against diseases resulting from pathogenic responses by specific T cell populations |
| US5837246A (en) * | 1989-03-21 | 1998-11-17 | The Immune Response Corporation | Vaccination and methods against diseases resulting from pathogenic responses by specific T cell populations |
| US5612035A (en) * | 1989-03-21 | 1997-03-18 | The Immune Response Corporation | Vaccination against diseases resulting from pathogenic responses by specific T cell populations |
| US5776459A (en) * | 1989-07-19 | 1998-07-07 | Connetics Corporation | TCR V beta 5 peptides |
| US5614192A (en) * | 1989-07-19 | 1997-03-25 | Connective Therapeutics, Inc. | T cell receptor peptides as therapeutics for immune-related disease |
| US5298396A (en) * | 1989-11-15 | 1994-03-29 | National Jewish Center For Immunology And Respiratory Medicine | Method for identifying T cells disease involved in autoimmune disease |
| WO1992001044A1 (en) * | 1990-07-06 | 1992-01-23 | Allergene, Inc. | Mouse/human heterohybrid cell line el41 and methods for the production of human monoclonal antibodies |
| US5668117A (en) * | 1991-02-22 | 1997-09-16 | Shapiro; Howard K. | Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments |
| US5211952A (en) * | 1991-04-12 | 1993-05-18 | University Of Southern California | Contraceptive methods and formulations for use therein |
| US6083503A (en) * | 1991-08-28 | 2000-07-04 | The United States Of America As Represented By The Department Of Health And Human Services | Interleukin-2 stimulated T lymphocyte cell death for the treatment of autoimmune diseases, allergic responses, and graft rejection |
| US5480895A (en) * | 1991-09-27 | 1996-01-02 | New York Society For The Relief Of The Ruptured And Crippled, Maintaining The Hospital For Special Surgery | Method of producing antibodies to a restricted population of T lymphocytes, antibodies produced therefrom and methods of use thereof |
| US5545716A (en) * | 1992-09-08 | 1996-08-13 | University Of Florida | Superantigen agonist and antagonist peptides |
| WO1994020120A1 (en) * | 1993-03-12 | 1994-09-15 | Cellcor, Inc. | In vitro assay measuring degree of activation of immune cells |
| US5494899A (en) * | 1993-04-07 | 1996-02-27 | Oklahoma Medical Research Foundation | Selective regulation of B lymphocyte precursors by hormones |
| IL110787A0 (en) * | 1993-08-27 | 1994-11-11 | Sandoz Ag | Biodegradable polymer, its preparation and pharmaceutical composition containing it |
| JPH09510437A (ja) * | 1993-12-28 | 1997-10-21 | カイロン ミモトープス プロプライエトリー リミテッド | Ｔ細胞エピトープ |
| US5552300A (en) * | 1994-01-13 | 1996-09-03 | T Cell Sciences, Inc. | T cell antigen receptor V region proteins and methods of preparation thereof |
| US6410518B1 (en) * | 1994-05-31 | 2002-06-25 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide inhibition of raf gene expression |
| US5723503A (en) * | 1994-09-28 | 1998-03-03 | Thomas Jefferson University | Biological treatment for rheumatoid arthritis |
| US5674487A (en) * | 1994-09-28 | 1997-10-07 | Univ Jefferson | Method for treating autoimmune diseases |
| US6033661A (en) * | 1995-06-07 | 2000-03-07 | Thomas Jefferson University | Composition and method for allogenetic mononuclear cell immunotherapy |
| US6096314A (en) * | 1994-10-07 | 2000-08-01 | Yeda Research And Development Co. Ltd. | Peptides and pharmaceutical compositions comprising them |
| EP1172376A1 (en) * | 1994-11-18 | 2002-01-16 | Neurocrine Biosciences, Inc. | Peptide analogues at position 91 of human myelin basic protein for treatment of multiple sclerosis |
| FR2727117A1 (fr) * | 1994-11-18 | 1996-05-24 | Geffard Michel | Utilisation de conjugues de la polylysine pour la preparation de medicaments utiles dans le traitement des maladies neurodegeneratives et des affections degeneratives a caractere autoimmun |
| US6218166B1 (en) * | 1994-12-09 | 2001-04-17 | John Wayne Cancer Institute | Adjuvant incorporation into antigen carrying cells: compositions and methods |
| US5874531A (en) * | 1995-03-07 | 1999-02-23 | President And Fellows Of Harvard College | Identification of self and non-self antigens implicated autoimmune disease |
| US5869057A (en) * | 1995-06-07 | 1999-02-09 | Rock; Edwin P. | Recombinant vaccines to break self-tolerance |
| SE9502921D0 (sv) * | 1995-08-23 | 1995-08-23 | Astra Ab | New compounds |
| US5739307A (en) * | 1995-08-28 | 1998-04-14 | Washington University | Polynucleotide encoding neurturin neurotrophic factor |
| US5716946A (en) * | 1996-02-13 | 1998-02-10 | Wisconsin Alumni Research Foundation | Multiple sclerosis treatment |
| US5750356A (en) * | 1996-05-31 | 1998-05-12 | Anergen, Inc. | Method for monitoring T cell reactivity |
| US5849886A (en) * | 1996-07-10 | 1998-12-15 | Oy Aboatech Ab | Extraction of myelin basic protein |
| US20010031253A1 (en) * | 1996-07-24 | 2001-10-18 | Gruenberg Micheal L. | Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease |
| US6130087A (en) * | 1996-10-07 | 2000-10-10 | Fordham University | Methods for generating cytotoxic T cells in vitro |
| KR20000049096A (ko) * | 1996-10-11 | 2000-07-25 | 린다 에스. 스티븐슨 | 혼합 림프구와 조합된 종양세포를 사용하는 암 면역요법 |
| US6054292A (en) * | 1997-07-18 | 2000-04-25 | Incyte Pharmaceuticals, Inc. | T-cell receptor protein |
| US20020009448A1 (en) * | 1997-09-19 | 2002-01-24 | Leslie P. Weiner | T-cell vaccination for the treatment of multiple sclerosis |
| US20020072493A1 (en) * | 1998-05-19 | 2002-06-13 | Yeda Research And Development Co. Ltd. | Activated T cells, nervous system-specific antigens and their uses |
| US20020001841A1 (en) * | 1998-06-26 | 2002-01-03 | Keld Kaltoft | Continuous t-cell lines |
| AU774952B2 (en) * | 1999-02-23 | 2004-07-15 | Baylor College Of Medicine | T cell receptor Vbeta-Dbeta-Jbeta sequence and methods for its detection |
| US6187750B1 (en) * | 1999-08-25 | 2001-02-13 | Everyoung Technologies, Inc. | Method of hormone treatment for patients with symptoms consistent with multiple sclerosis |
| US6746670B2 (en) * | 2000-08-15 | 2004-06-08 | Schering Corporation | Regulatory T cells; methods |
| SI1311542T1 (sl) * | 2000-08-21 | 2009-02-28 | Apitope Technology Bristol Ltd | Tolerogenski peptidi |
| JP2004535785A (ja) * | 2000-11-22 | 2004-12-02 | ディアデクサス インコーポレーテッド | 乳房特異的遺伝子およびタンパク質に関する組成物および方法 |
| US20030078347A1 (en) * | 2001-08-28 | 2003-04-24 | General Electric Company | Triazine compounds, polymers comprising triazine structural units, and method |
| US7658926B2 (en) * | 2001-09-14 | 2010-02-09 | Opexa Pharmaceuticals, Inc. | Autologous T-cell vaccines materials and methods |
| EP1444330A1 (en) * | 2001-11-07 | 2004-08-11 | Kirin Beer Kabushiki Kaisha | Expansion of t cells in vitro and expanded t cell populations |
| US20050181459A1 (en) * | 2002-06-11 | 2005-08-18 | Matthew Baker | Method for mapping and eliminating T cell epitopes |
| CA2542668C (en) * | 2003-10-17 | 2014-04-29 | Baylor College Of Medicine | A method for increasing cd8+ cytotoxic t cell reponses and for treating multiple sclerosis |
| CN101711861A (zh) * | 2003-10-31 | 2010-05-26 | 不列颠哥伦比亚大学 | 细菌毒力因子及其用途 |
| WO2005074579A2 (en) * | 2004-02-02 | 2005-08-18 | Mixture Sciences, Inc. | Peptide mixtures with immunomodulatory activity |
-
2007
- 2007-05-04 PT PT77973477T patent/PT2016414E/pt unknown
- 2007-05-04 AU AU2007247869A patent/AU2007247869B2/en not_active Ceased
- 2007-05-04 JP JP2009510114A patent/JP2009536036A/ja not_active Withdrawn
- 2007-05-04 EP EP07797347.7A patent/EP2016414B1/en not_active Not-in-force
- 2007-05-04 PT PT111886768T patent/PT2420833E/pt unknown
- 2007-05-04 ES ES11188676.8T patent/ES2552667T3/es active Active
- 2007-05-04 NZ NZ572644A patent/NZ572644A/en not_active IP Right Cessation
- 2007-05-04 CA CA002651328A patent/CA2651328A1/en not_active Abandoned
- 2007-05-04 EP EP13187264.0A patent/EP2712623A1/en not_active Withdrawn
- 2007-05-04 ES ES07797347T patent/ES2553192T3/es active Active
- 2007-05-04 EP EP11188676.8A patent/EP2420833B1/en not_active Not-in-force
- 2007-05-04 PL PL07797347T patent/PL2016414T3/pl unknown
- 2007-05-04 DK DK07797347.7T patent/DK2016414T3/en active
- 2007-05-04 US US12/299,585 patent/US20100003228A1/en not_active Abandoned
- 2007-05-04 WO PCT/US2007/068304 patent/WO2007131210A2/en not_active Ceased
- 2007-05-04 PL PL11188676T patent/PL2420833T3/pl unknown
- 2007-05-04 DK DK11188676.8T patent/DK2420833T3/en active
-
2008
- 2008-11-04 IL IL195115A patent/IL195115A/en not_active IP Right Cessation
-
2013
- 2013-08-06 JP JP2013163134A patent/JP6000205B2/ja not_active Expired - Fee Related
-
2016
- 2016-01-12 JP JP2016003678A patent/JP2016053090A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| NZ572644A (en) | 2012-06-29 |
| EP2420833B1 (en) | 2015-09-02 |
| EP2712623A1 (en) | 2014-04-02 |
| US20100003228A1 (en) | 2010-01-07 |
| AU2007247869B2 (en) | 2013-11-21 |
| IL195115A (en) | 2012-12-31 |
| EP2016414B1 (en) | 2015-09-02 |
| JP6000205B2 (ja) | 2016-09-28 |
| PT2016414E (pt) | 2015-11-24 |
| DK2420833T3 (en) | 2015-12-07 |
| JP2013252142A (ja) | 2013-12-19 |
| PL2420833T3 (pl) | 2016-03-31 |
| PL2016414T3 (pl) | 2016-01-29 |
| JP2016053090A (ja) | 2016-04-14 |
| JP2009536036A (ja) | 2009-10-08 |
| WO2007131210A2 (en) | 2007-11-15 |
| EP2420833A1 (en) | 2012-02-22 |
| ES2552667T3 (es) | 2015-12-01 |
| PT2420833E (pt) | 2015-11-24 |
| DK2016414T3 (en) | 2015-12-07 |
| IL195115A0 (en) | 2009-09-22 |
| EP2016414A2 (en) | 2009-01-21 |
| ES2553192T3 (es) | 2015-12-04 |
| WO2007131210A3 (en) | 2008-10-30 |
| AU2007247869A1 (en) | 2007-11-15 |
| EP2016414A4 (en) | 2009-08-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1812563B1 (en) | Methods of generating antigen-specific cd4+cd25+ regulatory t cells, compositions and methods of use | |
| Roberts et al. | Patients with lung cancer and paraneoplastic Hu syndrome harbor HuD-specific type 2 CD8+ T cells | |
| Varrin‐Doyer et al. | Aquaporin 4‐specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporter | |
| AU2007247869B2 (en) | T-cell vaccine | |
| WO2001094944A2 (en) | Artificial antigen presenting cells and methods of use thereof | |
| JP2010252806A (ja) | 同種抗原の特定方法、ならびに癌治療および移植へのその使用 | |
| Salvetti et al. | T-lymphocyte reactivity to the recombinant mycobacterial 65-and 70-kDa heat shock proteins in multiple sclerosis | |
| WO2016179288A1 (en) | Novel regulatory-cells, method for their isolation and uses | |
| Venken et al. | Memory CD4+ CD127high T cells from patients with multiple sclerosis produce IL-17 in response to myelin antigens | |
| JP2023166443A (ja) | 樹状細胞治療のための方法および使用 | |
| Zhang et al. | A polyclonal anti‐vaccine CD4 T cell response detected with HLA‐DP4 multimers in a melanoma patient vaccinated with MAGE‐3. DP4‐peptide‐pulsed dendritic cells | |
| EP1677821A1 (en) | A method for increasing cd8+ cytotoxic t cell reponses and for treating multiple sclerosis | |
| CN114080231A (zh) | 用于鉴定特异性攻击癌细胞的t细胞的特异性标记 | |
| AU2013204973A1 (en) | T-cell vaccine | |
| WO2008028229A1 (en) | Methods of identifying markers | |
| Ihantola | T-cell dysfunction and autoantigen recognition in type 1 diabetes | |
| Vaghela | T cell recognition of stress-induced post-translational modifications | |
| Hood | Equal recognition of self by mediators and suppressors while poor recognition leads to ignorance | |
| Antigen-Specific | Presentation of Acquired Peptide-MHC Class |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |
Effective date: 20170727 |